Increasing dominance of C. glabrata in northern Europe, the United States, and Canada has been observed while C. parapsilosis has become more prominent in southern Europe, Asia, and South America. Regional species distribution guides treatment recommendations since the species exhibit different susceptibilities to azole and echinocandin classes of antifungals.The virulence of Candida species differs considerably, with C. parapsilosis and C. krusei being less virulent than C. albicans, C. tropicalis, and C. glabrata. This variation is reflected in mortality rates. References
Further reading
Pfaller MA, Diekema DJ (2007). "Epidemiology of invasive candidiasis: a persistent public health problem". Clinical Microbiology Reviews. 20 (1): 133–163. doi:10.1128/CMR.00029-06. PMC 1797637. PMID 17223626. (Review). Yapar N (2014). "Epidemiology and risk factors for invasive candidiasis". Therapeutics and Clinical Risk Management. 10: 95–105. doi:10.2147/TCRM.S40160. PMC 3928396. PMID 24611015. (Review). External links

Candidiasis (Invasive) in the MSD (Merck) Manual
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
The cell-surface protein FrpC from Neisseria meningitidis has been engineered to allow covalent coupling between proteins, because it generates a reactive anhydride when exposed to calcium. The bacterium also expresses unique enzymes able to cleave IgA antibodies. See also
DNA uptake sequence DNA taken up by Neisseria
NmVac4-A/C/Y/W-135 polysaccharide vaccine
Sara Branham Matthews microbiologist
Shwartzman phenomenon
Sepsis

References
External links
"Neisseria meningitidis". NCBI Taxonomy Browser. 487. Type strain of Neisseria meningitidis at BacDive - the Bacterial Diversity Metadatabase